Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Jul 1;72(3):310-3.
doi: 10.1097/QAI.0000000000000964.

Brief Report: Relationship Among Viral Load Outcomes in HIV Treatment Interruption Trials

Graham C Treasure  1 , Evgenia Aga, Ronald J Bosch, John W Mellors, Daniel R Kuritzkes, Michael Para, Rajesh T Gandhi, Jonathan Z Li
Affiliations

Brief Report: Relationship Among Viral Load Outcomes in HIV Treatment Interruption Trials

Graham C Treasure et al. J Acquir Immune Defic Syndr. .

Abstract

Viral load (VL) rebound timing and set point were analyzed in 235 participants undergoing analytic treatment interruption (ATI) in 6 AIDS Clinical Trials Group studies. There was no significant association between rebound timing and ATI VL set point for those who rebounded ≤12 weeks. VL set points were lower in participants with rebound >12 weeks (P < 0.001) and participants treated during early infection (P < 0.001). Pre-antiretroviral therapy VL correlated with set point, though 68% of participants had a set point lower than pre-antiretroviral therapy VL. These results illustrate complex relationships between post-ATI virologic outcomes and the potential presence of biological factors mediating rebound timing and set point.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Analysis of post-ATI VL endpoints
A) VL set points and median by rebound category. B) Median VLs categorized by viral rebound week using a two week window for each time point with the number of observations per category per time point listed below. C) VLs for all patients shown, with median VLs of chronic and acutely-treated participants in solid and dashed lines, respectively.
Figure 2
Figure 2. Relationship of pre-ART Viral Load and Post-ATI Set Point
A) Plot of pre-ART VL vs. set point for 95 chronically infected patients for whom data were available. B) Percentile data for fold change of ATI VL Set Point to Pre-ART VL (non log10 transformed). Fold change represents post-ATI set point divided by pre-ART viral load.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Angel JB, Routy JP, Tremblay C, et al. A randomized controlled trial of HIV therapeutic vaccination using ALVAC with or without Remune. AIDS. 2011;25:731–9. - PubMed
    1. Schooley RT, Spritzler J, Wang H, et al. AIDS clinical trials group 5197: a placebo-controlled trial of immunization of HIV-1-infected persons with a replication-deficient adenovirus type 5 vaccine expressing the HIV-1 core protein. J Infect Dis. 2010;202:705–16. - PMC - PubMed
    1. Garcia F, Climent N, Guardo AC, et al. A dendritic cell-based vaccine elicits T cell responses associated with control of HIV-1 replication. Sci Transl Med. 2013;5:166ra2. - PubMed
    1. Li JZ, Smith DM, Mellors JW. The need for treatment interruption studies and biomarker identification in the search for an HIV cure. AIDS. 2015;29:1429–32. - PMC - PubMed
    1. Number of persons tested for HIV--United States, 2002. MMWR Morb Mortal Wkly Rep. 2004;53:1110–3. - PubMed

Publication types